Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/115634
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcEwan, P.-
dc.contributor.authorBennett, H.-
dc.contributor.authorWard, T.-
dc.contributor.authorWebster, S.-
dc.contributor.authorGordon, J.-
dc.contributor.authorKalsekar, A.-
dc.contributor.authorYuan, Y.-
dc.contributor.authorBrenner, M.-
dc.date.issued2016-
dc.identifier.citationEuropean Journal of Gastroenterology and Hepatology, 2016; 28(2):173-180-
dc.identifier.issn0954-691X-
dc.identifier.issn1473-5687-
dc.identifier.urihttp://hdl.handle.net/2440/115634-
dc.description.abstractAbstract not available-
dc.description.statementofresponsibilityPhil McEwan, Hayley Bennett, Thomas Ward, Samantha Webster, Jason Gordon, Anupama Kalsekar, Yong Yuan and Michael Brenner-
dc.language.isoen-
dc.publisherLippincott Williams & Wilkins-
dc.rights© 2016 Wolters Kluwer Health, Inc. All rights reserved.-
dc.source.urihttp://dx.doi.org/10.1097/meg.0000000000000510-
dc.subjectPhenotype-
dc.titleThe cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK-
dc.typeJournal article-
dc.identifier.doi10.1097/MEG.0000000000000510-
pubs.publication-statusPublished-
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.